Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/176870
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease

AuthorsZarei, Mohammad; Barroso, Emma; Palomer, Xavier; Dai, Jianli; Rada, Patricia; Quesada-López, Tania; Escolà-Gil, Joan Carles; Cedó, Lídia; Reza Zali, Mohammad; Molaei, Mahsa; Dabiri, Reza; Vázquez, Santiago; Pujol, Eugènia; Valverde, Ángela M. ; Villarroya, Francesc; Liu, Yong; Wahli, Walter; Vázquez-Carrera, Manuel
Issue DateFeb-2018
PublisherElsevier
CitationMolecular Metabolism 8: 117-131 (2018)
Abstract[Objective] The very low-density lipoprotein receptor (VLDLR) plays an important role in the development of hepatic steatosis. In this study, we investigated the role of Peroxisome Proliferator-Activated Receptor (PPAR)b/d and fibroblast growth factor 21 (FGF21) in hepatic VLDLR regulation. [Methods] Studies were conducted in wild-type and Pparb/d-null mice, primary mouse hepatocytes, human Huh-7 hepatocytes, and liver biopsies from control subjects and patients with moderate and severe hepatic steatosis. [Results] Increased VLDLR levels were observed in liver of Pparb/d-null mice and in Pparb/d-knocked down mouse primary hepatocytes through mechanisms involving the heme-regulated eukaryotic translation initiation factor 2a (eIF2a) kinase (HRI), activating transcription factor (ATF) 4 and the oxidative stress-induced nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways. Moreover, by using a neutralizing antibody against FGF21, Fgf21-null mice and by treating mice with recombinant FGF21, we show that FGF21 may protect against hepatic steatosis by attenuating endoplasmic reticulum (ER) stress-induced VLDLR upregulation. Finally, in liver biopsies from patients with moderate and severe hepatic steatosis, we observed an increase in VLDLR levels that was accompanied by a reduction in PPARb/d mRNA abundance and DNA-binding activity compared with control subjects. [Conclusions]: Overall, these findings provide new mechanisms by which PPARb/d and FGF21 regulate VLDLR levels and influence hepatic steatosis development.
Publisher version (URL)https://doi.org/10.1016/j.molmet.2017.12.008
URIhttp://hdl.handle.net/10261/176870
DOI10.1016/j.molmet.2017.12.008
E-ISSN2212-8778
Appears in Collections:(IIBB) Artículos
(IIBM) Artículos

Files in This Item:
File Description SizeFormat
Hepatic regulation_Zarei.htm96,99 kBHTMLView/Open
Show full item record
Review this work

PubMed Central
Citations

24
checked on Nov 28, 2021

SCOPUSTM   
Citations

39
checked on Nov 23, 2021

WEB OF SCIENCETM
Citations

37
checked on Nov 23, 2021

Google ScholarTM

Check

Altmetric

Dimensions


Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.